7.81
-0.35(-4.29%)
Currency In USD
| Previous Close | 8.16 |
| Open | 8.02 |
| Day High | 8.35 |
| Day Low | 7.79 |
| 52-Week High | 54.95 |
| 52-Week Low | 5.01 |
| Volume | 4,294 |
| Average Volume | 178,154 |
| Market Cap | 4.59M |
| PE | -0.23 |
| EPS | -34.62 |
| Moving Average 50 Days | 8.72 |
| Moving Average 200 Days | 14.02 |
| Change | -0.35 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.49 as of July 30, 2025 at a share price of $7.81. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $4.04 as of July 30, 2025 at a share price of $7.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals Provides Product Portfolio Update
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data Topical Rapa
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
GlobeNewswire Inc.
Jun 26, 2025 12:30 PM GMT
New episode spotlights the severe burden of Netherton Syndrome in infants and children, reinforcing the need for effective pediatric treatmentsASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
GlobeNewswire Inc.
Jun 24, 2025 12:30 PM GMT
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and